Literature DB >> 26242182

Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

A M Vannucchi1, T Barbui2, F Cervantes3, C Harrison4, J-J Kiladjian5, N Kröger6, J Thiele7, C Buske8.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26242182     DOI： 10.1093/annonc/mdv203

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  35 in total

Review 1.  JAK2 inhibitors for myeloproliferative neoplasms: what is next?

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Blood       Date:  2017-05-12       Impact factor: 22.113

Review 2.  SOHO State-of-the-Art Update and Next Questions: MPN.

Authors:  Prithviraj Bose; Jason Gotlib; Claire N Harrison; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2018-01

3.  Ruxolitinib for the management of myelofibrosis: Results of an international physician survey.

Authors:  Martin H Ellis; Maya Koren-Michowitz; Noa Lavi; Alessandro M Vannucchi; Ruben Mesa; Claire N Harrison
Journal:  Leuk Res       Date:  2017-08-10       Impact factor: 3.156

Review 4.  Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

Authors:  Tiziano Barbui; Ayalew Tefferi; Alessandro M Vannucchi; Francesco Passamonti; Richard T Silver; Ronald Hoffman; Srdan Verstovsek; Ruben Mesa; Jean-Jacques Kiladjian; Rȕdiger Hehlmann; Andreas Reiter; Francisco Cervantes; Claire Harrison; Mary Frances Mc Mullin; Hans Carl Hasselbalch; Steffen Koschmieder; Monia Marchetti; Andrea Bacigalupo; Guido Finazzi; Nicolaus Kroeger; Martin Griesshammer; Gunnar Birgegard; Giovanni Barosi
Journal:  Leukemia       Date:  2018-02-27       Impact factor: 11.528

Review 5.  What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia?

Authors:  Alessandro M Vannucchi; Paola Guglielmelli
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 6.  No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials.

Authors:  Tiziano Barbui; Alessandra Carobbio; Arianna Ghirardi; Arianna Masciulli; Alessandro Rambaldi; Alessandro M Vannucchi
Journal:  Haematologica       Date:  2017-03-02       Impact factor: 9.941

Review 7.  The role of thrombocytapheresis in the contemporary management of hyperthrombocytosis in myeloproliferative neoplasms: A case-based review.

Authors:  Prajwal Boddu; Lorenzo Falchi; Chitra Hosing; Kate Newberry; Prithviraj Bose; Srdan Verstovsek
Journal:  Leuk Res       Date:  2017-03-22       Impact factor: 3.156

8.  Austrian recommendations for the management of primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis: an expert statement.

Authors:  Thamer Sliwa; Christine Beham-Schmid; Sonja Burgstaller; Veronika Buxhofer-Ausch; Günther Gastl; Klaus Geissler; Maria Krauth; Peter Krippl; Alois Lang; Andreas Petzer; Stefan Wöhrer; Albert Wölfler; Heinz Gisslinger
Journal:  Wien Klin Wochenschr       Date:  2016-12-13       Impact factor: 1.704

9.  β-Arrestin2 mediates progression of murine primary myelofibrosis.

Authors:  Lindsay Am Rein; James W Wisler; Jihee Kim; Barbara Theriot; LiYin Huang; Trevor Price; Haeyoon Yang; Minyong Chen; Wei Chen; Dorothy Sipkins; Yuri Fedoriw; Julia Kl Walker; Richard T Premont; Robert J Lefkowitz
Journal:  JCI Insight       Date:  2017-12-21

Review 10.  Developmental Therapeutics in Myeloproliferative Neoplasms.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.